AAOS Explores a Post-COVID Return to Normal. It Won’t Be Easy

article image

As a prolonged pandemic takes its toll, a subdued AAOS met to look ahead at the impact of regulatory and reimbursement changes on different aspects of orthopedics, including orthobiologics and the scientific advances that are rapidly changing the regenerative medicine field.

The American Association of Orthopedic Surgeons’ (AAOS) annual meeting in San Diego in late August/early September, was a first in many respects—one of the first major medical meetings to go live, in-person only, and for many attendees it was the first pandemic-era business trip.It was a brave, stubborn, and ultimately informative event that highlighted the organization’s pressing priorities as its members manage through COVID-19 and, even more urgently, reimbursement shifts that are driving structural changes in their practices. (See “Canaccord’s Kyle Rose Previews Innovation, COVID-Era Uncertainty at Upcoming AAOS,” MedTech Strategist, August 26, 2021.)


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: